NASDAQ:AGENAgenus Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Agenus Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.02 0.00 (0.00 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$3.95Now: $4.02▼$4.1150-Day Range$2.29MA: $3.48▼$4.2452-Week Range$1.82Now: $4.02▼$4.78Volume1.25 million shsAverage Volume3.00 million shsMarket Capitalization$672.87 millionP/E RatioN/ADividend YieldN/ABeta2.08 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neoantigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neoepitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAgenus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Agenus has a potential upside of 49.3% from its current price of $4.02.Amount of Analyst CoverageAgenus has only been the subject of 1 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesAgenus has received 434 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAgenus has received 336 “underperform” votes. (Add your “underperform” vote.)Community SentimentAgenus has received 56.36% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote “Outperform” if you believe AGEN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAgenus does not currently pay a dividend.Dividend GrowthAgenus does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agenus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,847,418.00 in company stock.Percentage Held by InsidersOnly 5.20% of the stock of Agenus is held by insiders.Percentage Held by Institutions46.74% of the stock of Agenus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Agenus are expected to remain at ($1.05) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agenus is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agenus is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.46 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:AGEN Previous Symbol CUSIP00847G70 CIK1098972 Webagenusbio.com Phone781-674-4400Debt Debt-to-Equity RatioN/A Current Ratio0.81 Quick Ratio0.81Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$150.05 million Price / Sales4.48 Cash FlowN/A Price / Cash FlowN/A Book Value($1.68) per share Price / Book-2.39Profitability EPS (Most Recent Fiscal Year)($0.80) Net Income$-107,660,000.00 Net Margins-204.33% Return on EquityN/A Return on Assets-97.23%Miscellaneous Employees294 Outstanding Shares167,380,000Market Cap$672.87 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:AGEN Rates by TradingView Receive AGEN News and Ratings via Email Sign-up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Agenus (NASDAQ:AGEN) Frequently Asked Questions How has Agenus' stock been impacted by COVID-19 (Coronavirus)? Agenus' stock was trading at $2.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AGEN stock has increased by 47.8% and is now trading at $4.02. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Agenus? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Agenus. When is Agenus' next earnings date? Agenus is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Agenus. How were Agenus' earnings last quarter? Agenus Inc (NASDAQ:AGEN) released its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.02. The biotechnology company had revenue of $15.13 million for the quarter, compared to the consensus estimate of $12.35 million. View Agenus' earnings history. What price target have analysts set for AGEN? 1 analysts have issued 12 month price targets for Agenus' stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Agenus' share price to reach $6.00 in the next year. This suggests a possible upside of 49.3% from the stock's current price. View analysts' price targets for Agenus. Has Agenus been receiving favorable news coverage? News headlines about AGEN stock have trended negative on Saturday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Agenus earned a news impact score of -2.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Agenus. Who are some of Agenus' key competitors? Some companies that are related to Agenus include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors. What other stocks do shareholders of Agenus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include Rosetta Genomics (ROSG), Exelixis (EXEL), REDHILL BIOPHAR/S (RDHL), Merrimack Pharmaceuticals (MACK), Opko Health (OPK), Gilead Sciences (GILD), Novavax (NVAX), Energy Transfer LP Unit (ET), Sorrento Therapeutics (SRNE) and Inovio Pharmaceuticals (INO). Who are Agenus' key executives? Agenus' management team includes the following people: Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 66)Dr. Jennifer Buell, Chief Operating OfficerDr. Alexander R. Duncan, CTO & Head of Research (Age 57)Dr. Christian Cortis, Chief Strategy Officer & Head of Fin. (Age 51)Ms. Christine M. Klaskin, Principal Accounting Officer & VP of Fin. (Age 53) What is Agenus' stock symbol? Agenus trades on the NASDAQ under the ticker symbol "AGEN." How do I buy shares of Agenus? Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Agenus' stock price today? One share of AGEN stock can currently be purchased for approximately $4.02. How big of a company is Agenus? Agenus has a market capitalization of $672.87 million and generates $150.05 million in revenue each year. The biotechnology company earns $-107,660,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Agenus employs 294 workers across the globe. What is Agenus' official website? The official website for Agenus is agenusbio.com. How can I contact Agenus? Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected] This page was last updated on 7/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
